Biotech Values

[Biowatch]

Desmoteplase study back

http://biz.yahoo.com/prnews/061027/nyf113.html?.v=5

Patient Recruitment to Resume Without Modification of Protocol for Desmoteplase Phase IIB/III Stroke Study DIAS-2
Friday October 27, 11:08 pm ET [!]

NEW YORK, Oct. 27 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX - News) and its development partner for desmoteplase, PAION AG (Aachen, Germany), today announced that the independent Data Monitoring Committee (DMC) for the DIAS-2 Phase IIB/III study met and informed the Steering Committee and the Companies that it has reviewed the cumulative data from the study provided by the Companies and recommended the resumption of patient enrollment into DIAS-2 with no modification of the protocol. At this meeting, the DMC reviewed data from 170 randomized subjects. The DIAS-2 study is evaluating PAION's drug candidate desmoteplase in patients with acute ischemic stroke. The Companies continue to expect that enrolment will be completed by the end of 2006 and that study results will be available by the middle of 2007.